Literature DB >> 1365816

Selective inhibition of arthropod-borne and arenaviruses in vitro by 3'-fluoro-3'-deoxyadenosine.

D F Smee1, J L Morris, D L Barnard, A Van Aerschot.   

Abstract

A novel nucleoside analog, 3'-fluoro-3'-deoxyadenosine (3'F3'dAdo), was evaluated for antiviral activity against several arthropod-borne and arenaviruses in Vero cell culture. The following 50% inhibitory concentrations (EC50) of virus plaque formation were obtained against the test viruses: Semliki Forest (10.3 microM) and Venezuelan equine encephalitis (5.3 microM) alphaviruses, lymphocytic choriomeningitis (7.7 microM) and Pichinde (greater than 32 microM) arenaviruses, Punta Toro (greater than 32 microM) and San Angelo (1.6 microM) bunyaviruses, banzi flavivirus (4.0 microM), and Colorado tick fever orbivirus (0.6 microM). By comparison, the broad-spectrum antiviral agent ribavirin was active against lymphocytic choriomeningitis (18 microM), Pichinde (24 microM), Punta Toro (114 microM), and San Angelo (99 microM) viruses, but was less active against the other 4 viruses (greater than 200 microM). Vero cell proliferation and thymidine and uridine incorporation into replicating Vero cells were inhibited by 50% with 3'F3'dAdo concentrations of 36, 45, and 32 microM, respectively. In virus yield reduction assays, increasing the multiplicity of infections of Semliki Forest and Venezuelan equine encephalitis viruses reduced the inhibitory activity of 3'F3'dAdo. Using the same assay, 3'F3'dAdo was found to enhance Punta Toro virus replication up to 5-fold relative to the untreated control. By adding the nucleoside transport inhibitor nitrobenzylthioinosine (100 microM) to the culture medium, antiviral activity against the two alphaviruses was eliminated, indicating that 3'F3'dAdo uses the nucleoside transport system for cell entry. When actinomycin D (5 microM) was used to greatly suppress cellular RNA synthesis in Semliki Forest virus-infected and uninfected cells, 3'F3'dAdo preferentially inhibited viral RNA synthesis. The results of these studies indicate 3'F3'dAdo is a selective inhibitor of most of the viruses tested and should be a promising candidate for in vivo evaluations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365816     DOI: 10.1016/0166-3542(92)90035-4

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  5 in total

1.  Broad-Spectrum Antiviral Activity of 3'-Deoxy-3'-Fluoroadenosine against Emerging Flaviviruses.

Authors:  Luděk Eyer; Pavel Svoboda; Jan Balvan; Tomáš Vičar; Matina Raudenská; Michal Štefánik; Jan Haviernik; Ivana Huvarová; Petra Straková; Ivo Rudolf; Zdeněk Hubálek; Katherine Seley-Radtke; Erik de Clercq; Daniel Růžek
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Nucleoside inhibitors of tick-borne encephalitis virus.

Authors:  Luděk Eyer; James J Valdés; Victor A Gil; Radim Nencka; Hubert Hřebabecký; Michal Šála; Jiří Salát; Jiří Černý; Martin Palus; Erik De Clercq; Daniel Růžek
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

3.  Biodistribution and PET imaging of [(18)F]-fluoroadenosine derivatives.

Authors:  Mian M Alauddin; Antranik Shahinian; Ryan Park; Michael Tohme; John D Fissekis; Peter S Conti
Journal:  Nucl Med Biol       Date:  2007-02-22       Impact factor: 2.408

4.  Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds.

Authors:  Cybele C García; Mahmoud Djavani; Ivan Topisirovic; Katherine L B Borden; María S Salvato; Elsa B Damonte
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

5.  Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro.

Authors:  Stephan Günther; Marcel Asper; Christina Röser; Luciano K S Luna; Christian Drosten; Beate Becker-Ziaja; Peter Borowski; Huan-Ming Chen; Ramachandra S Hosmane
Journal:  Antiviral Res       Date:  2004-09       Impact factor: 5.970

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.